FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Hikma Pharmaceuticals USA Inc. to market a buprenorphine hydrochloride and naloxone hydrochloride dihydrate product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Buprenorphine hydrochloride and naloxone hydrochloride dihydrate (buprenorphine hydrochloride and naloxone hydrochloride dihydrate)

Snippet

SUPPL AP for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE)